555(top 0.1%)
PR articles
62.6K(top 0.1%)
PR citations
116(top 0.1%)
PR h-index
135(top 0.1%)
h-index
616
documents
84.0K
doc citations
4.5K
citing journals
100
times ranked

Publications

556 PR articles • 64,822 PR citations • Sorted by year • Download PDF (PDF by citations)
Sort: Year | Citations
#ArticleIFCitationsLinks
1Tumor-associated antigen PRAME exhibits dualistic functions that are targetable in diffuse large B cell lymphoma
Journal of Clinical Investigation, 2022, 132,
10.621Citations (PDF)
2Impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of false-negative MYC IHC
Blood, 2021, ,
4.222Citations (PDF)
3Genomic predictors of central nervous system relapse in primary testicular diffuse large B-cell lymphoma
Blood, 2021, 137, 1256-1259
4.222Citations (PDF)
4BCL2 Expression in First-Line Diffuse Large B-Cell Lymphoma Identifies a Patient Population With Poor Prognosis
Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 267-278.e10
1.012Citations (PDF)
5Long-term outcomes of R-CEOP show curative potential in patients with DLBCL and a contraindication to anthracyclines
Blood Advances, 2021, 5, 1483-1489
5.038Citations (PDF)
6Characterization of DLBCL with a PMBL gene expression signature
Blood, 2021, 138, 136-148
4.233Citations (PDF)
7Outcome of limited-stage nodular lymphocyte-predominant Hodgkin lymphoma and the impact of a PET-adapted approach
Blood Advances, 2021, 5, 3647-3655
5.04Citations (PDF)
8Single Cell Phenotypic Profiling of 27 DLBCL Cases Reveals Marked Intertumoral and Intratumoral Heterogeneity
Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2020, 97, 620-629
2.516Citations (PDF)
9Expansion of PD1-positive T Cells in Nodal Marginal Zone Lymphoma
American Journal of Surgical Pathology, 2020, 44, 657-664
3.531Citations (PDF)
10A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408
Clinical Cancer Research, 2020, 26, 4468-4477
6.820Citations (PDF)
11TMEM30A loss-of-function mutations drive lymphomagenesis and confer therapeutically exploitable vulnerability in B-cell lymphoma
Nature Medicine, 2020, 26, 577-588
33.067Citations (PDF)
12Coding and noncoding drivers of mantle cell lymphoma identified through exome and genome sequencing
Blood, 2020, 136, 572-584
4.265Citations (PDF)
13Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma
Blood, 2019, 134, 802-813
4.2118Citations (PDF)
14Targetable genetic alterations of <i>TCF4</i> ( <i>E2-2</i> ) drive immunoglobulin expression in diffuse large B cell lymphoma
Science Translational Medicine, 2019, 11,
12.560Citations (PDF)
15The whole-genome landscape of Burkitt lymphoma subtypes
Blood, 2019, 134, 1598-1607
4.2163Citations (PDF)
16Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition
Cancer Discovery, 2019, 9, 546-563
25.1287Citations (PDF)
17Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab
2019, 7,
21Citations (PDF)
18Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma
Journal of Clinical Oncology, 2019, 37, 190-201
16.9368Citations (PDF)
19Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma
Blood, 2019, 133, 1664-1676
4.2242Citations (PDF)
20Molecular features of a large cohort of primary central nervous system lymphoma using tissue microarray
Blood Advances, 2019, 3, 3953-3961
5.031Citations (PDF)
21Somatic IL4R mutations in primary mediastinal large B-cell lymphoma lead to constitutive JAK-STAT signaling activation
Blood, 2018, 131, 2036-2046
4.255Citations (PDF)
22Assessment of Capture and Amplicon-Based Approaches for the Development of a Targeted Next-Generation Sequencing Pipeline to Personalize Lymphoma Management
Journal of Molecular Diagnostics, 2018, 20, 203-214
2.577Citations (PDF)
23Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
New England Journal of Medicine, 2018, 378, 1396-1407
34.61,978Citations (PDF)
24AICDA drives epigenetic heterogeneity and accelerates germinal center-derived lymphomagenesis
Nature Communications, 2018, 9,
13.765Citations (PDF)
25Rapid, real time pathology review for ECOG/ACRIN 1412: a novel and successful paradigm for future lymphoma clinical trials in the precision medicine era
Blood Cancer Journal, 2018, 8,
5.510Citations (PDF)
26Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis
Cancer, 2018, 124, 136-144
4.056Citations (PDF)
27FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy
Blood, 2018, 131, 226-235
4.239Citations (PDF)
28High-resolution architecture and partner genes of MYC rearrangements in lymphoma with DLBCL morphology
Blood Advances, 2018, 2, 2755-2765
5.0101Citations (PDF)
29Genome-wide discovery of somatic regulatory variants in diffuse large B-cell lymphoma
Nature Communications, 2018, 9,
13.7133Citations (PDF)
30A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome
Blood, 2018, 132, 413-422
4.2101Citations (PDF)
31Duodenal-type and nodal follicular lymphomas differ by their immune microenvironment rather than their mutation profiles
Blood, 2018, 132, 1695-1702
4.265Citations (PDF)
32A multiprotein supercomplex controlling oncogenic signalling in lymphoma
Nature, 2018, 560, 387-391
37.9372Citations (PDF)
33Non-Hodgkin lymphoma
Lancet, The, 2017, 390, 298-310
62.3729Citations (PDF)
34The Genetic Basis of Hepatosplenic T-cell Lymphoma
Cancer Discovery, 2017, 7, 369-379
25.1186Citations (PDF)
35Can histologic transformation of follicular lymphoma be predicted and prevented?
Blood, 2017, 130, 258-266
4.265Citations (PDF)
36Enteropathy-associated T cell lymphoma subtypes are characterized by loss of function of SETD2
Journal of Experimental Medicine, 2017, 214, 1371-1386
9.2175Citations (PDF)
37Follicular lymphoma: State‐of‐the‐art ICML workshop in Lugano 2015
Hematological Oncology, 2017, 35, 397-407
2.111Citations (PDF)
38A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Clinical Cancer Research, 2017, 23, 4127-4137
6.8157Citations (PDF)
39Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell-of-origin–specific clinical impact
Blood, 2017, 129, 2760-2770
4.2126Citations (PDF)
40Adult high-grade B-cell lymphoma with Burkitt lymphoma signature: genomic features and potential therapeutic targets
Blood, 2017, 130, 1819-1831
4.276Citations (PDF)
41Observation as the initial management strategy in patients with mantle cell lymphoma
Annals of Oncology, 2017, 28, 2489-2495
10.080Citations (PDF)
42Diffuse large B‐cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab era
British Journal of Haematology, 2017, 176, 210-221
2.795Citations (PDF)
43CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas
Cancer Discovery, 2017, 7, 38-53
25.1257Citations (PDF)
44Outcome of primary cutaneous anaplastic large cell lymphoma: a 20‐year British Columbia Cancer Agency experience
British Journal of Haematology, 2017, 176, 234-240
2.726Citations (PDF)
45Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL
Blood Advances, 2017, 1, 2600-2609
5.076Citations (PDF)
46Prognostic Model to Predict Post-Autologous Stem-Cell Transplantation Outcomes in Classical Hodgkin Lymphoma
Journal of Clinical Oncology, 2017, 35, 3722-3733
16.952Citations (PDF)
47ROBUST: Lenalidomide-R-Chop Versus Placebo-R-Chop in Previously Untreated Abc-Type Diffuse Large B-Cell Lymphoma
Future Oncology, 2016, 12, 1553-1563
2.393Citations (PDF)
48Personalized risk prediction for event‐free survival at 24 months in patients with diffuse large B‐cell lymphoma
American Journal of Hematology, 2016, 91, 179-184
6.547Citations (PDF)
49Rituximab extended schedule or retreatment trial for low tumour burden non‐follicular indolent B‐cell non‐Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402
British Journal of Haematology, 2016, 173, 867-875
2.745Citations (PDF)
50General Biomarker Recommendations for Lymphoma
Journal of the National Cancer Institute, 2016, 108, djw250
4.63Citations (PDF)
51Molecular etiology of an indolent lymphoproliferative disorder determined by whole-genome sequencing
Journal of Physical Education and Sports Management, 2016, 2, a000679
1.43Citations (PDF)
52Targeting Non-proteolytic Protein Ubiquitination for the Treatment of Diffuse Large B Cell Lymphoma
Cancer Cell, 2016, 29, 494-507
33.0101Citations (PDF)
53Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL
Blood, 2016, 127, 2182-2188
4.2163Citations (PDF)
54Comprehensive characterization of programmed death ligand structural rearrangements in B-cell non-Hodgkin lymphomas
Blood, 2016, 128, 1206-1213
4.251Citations (PDF)
55Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy
Blood, 2016, 128, 1112-1120
4.2215Citations (PDF)
56Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells
Cell, 2016, 167, 405-418.e13
33.7239Citations (PDF)
57The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study
Lancet Haematology,the, 2016, 3, e467-e479
9.669Citations (PDF)
58EZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to Repress Bivalent Promoters, Mediate Germinal Center Formation and Lymphomagenesis
Cancer Cell, 2016, 30, 197-213
33.0233Citations (PDF)
59Impaired functional responses in follicular lymphoma CD8+TIM-3+T lymphocytes following TCR engagement
OncoImmunology, 2016, 5, e1224044
5.435Citations (PDF)
60Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell–derived lymphomas
Blood, 2016, 128, 1490-1502
4.2295Citations (PDF)
61Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease
Blood, 2016, 127, 2203-2213
4.278Citations (PDF)
62Randomized phase 3 study in low‐grade lymphoma comparing maintenance anti‐CD20 antibody with observation after induction therapy: A trial of the ECOG‐ACRIN Cancer Research Group (E1496)
Cancer, 2016, 122, 2996-3004
4.031Citations (PDF)
63Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia
Nature Communications, 2016, 7,
13.7109Citations (PDF)
64Toward Personalized Lymphoma Immunotherapy: Identification of Common Driver Mutations Recognized by Patient CD8+ T Cells
Clinical Cancer Research, 2016, 22, 2226-2236
6.828Citations (PDF)
65The value of routine bone marrow biopsy in patients with diffuse large B-cell lymphoma staged with PET/CT: a Danish-Canadian study
Annals of Oncology, 2016, 27, 1095-1099
10.049Citations (PDF)
66Fc Gamma Receptor 3A and 2A Polymorphisms Do Not Predict Response to Rituximab in Follicular Lymphoma
Clinical Cancer Research, 2016, 22, 821-826
6.828Citations (PDF)
67Diffuse large B-cell lymphoma cell-of-origin classification using the Lymph2Cx assay in the context of BCL2 and MYC expression status
Leukemia and Lymphoma, 2016, 57, 717-720
1.413Citations (PDF)
68Combined copy number and mutation analysis identifies oncogenic pathways associated with transformation of follicular lymphoma
Leukemia, 2016, 31, 83-91
7.7109Citations (PDF)
69Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by 90Y-ibritumomab tiuxetan: 10-year follow-up of the phase 2 ECOG-ACRIN study E1499
Leukemia, 2016, 31, 517-519
7.715Citations (PDF)
70A Novel Prognostic Model Based on Tumor Microenvironment Biology in Relapse Biopsies Predicts Post-Autologous Stem Cell Transplantation Outcomes in Classical Hodgkin Lymphoma
Blood, 2016, 128, 1093-1093
4.212Citations (PDF)
71DNA Copy Number Gains of TCF4 (E2-2) Are Associated with Poor Outcome in Diffuse Large B-Cell Lymphoma
Blood, 2016, 128, 2686-2686
4.21Citations (PDF)
72Serum Biomarkers Predict Outcomes in Advanced Hodgkin Lymphoma Independent of International Prognostic Score (IPS) and Treatment: Correlative Analysis from a Large North American Cooperative Group Trial
Blood, 2016, 128, 2992-2992
4.25Citations (PDF)
73Molecular Subgroups of Peripheral T-Cell Lymphoma Evolve By Distinct Genetic Pathways
Blood, 2016, 128, 4096-4096
4.21Citations (PDF)
74Histological Transformation and Progression in Follicular Lymphoma: A Clonal Evolution Study
PLoS Medicine, 2016, 13, e1002197
8.1227Citations (PDF)
75Gray Zone Lymphoma (GZL) with Features Intermediate Between Diffuse Large B-Cell Lymphoma (DLBCL) and Classical Hodgkin Lymphoma (cHL): Pathologic Classification and Clinical Outcomes from a Multicenter Consensus Study
Blood, 2016, 128, 4145-4145
4.20Citations (PDF)
76Targeted Sequencing Reveals Novel Gene Mutations Associated with Transformation and Early Progression in Follicular Lymphoma
Blood, 2016, 128, 2919-2919
4.25Citations (PDF)
77Crebbp Mutations Disrupt Dynamic Enhancer Acetylation in B-Cells, Enabling HDAC3 to Drive Lymphomagenesis
Blood, 2016, 128, 735-735
4.20Citations (PDF)
78Frequent Genetic Alterations of PI3K-AKT Pathway and Their Clinical Significance in Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma
Blood, 2016, 128, 607-607
4.21Citations (PDF)
79Revealing the Tumor Ecosystem in Follicular Lymphoma By Mass Cytometry
Blood, 2016, 128, 2939-2939
4.20Citations (PDF)
80The Role of UBR5 Mutations in the Pathogenesis of Mantle CELL Lymphoma
Blood, 2016, 128, 4124-4124
4.20Citations (PDF)
81Divergent Modes of Tumor Evolution Underlie Histological Transformation and Early Progression of Follicular Lymphoma
Blood, 2016, 128, 1091-1091
4.20Citations (PDF)
82Characterization of Genomic Rearrangements Involving CIITA and SOCS1 Using Targeted Capture Sequencing of Archival Tissue Specimens
Blood, 2016, 128, 2925-2925
4.20Citations (PDF)
83Comprehensive Genomic Analysis of Adult Burkitt Lymphoma Identifies the B-Cell Receptor Signaling Pathway As a Potential Therapeutic Target
Blood, 2016, 128, 4095-4095
4.20Citations (PDF)
84Genomic Alterations in CIITA Are Frequent in Primary Mediastinal Large B Cell Lymphoma and Are Associated with Diminished MHC Class II Expression
Cell Reports, 2015, 13, 1418-1431
6.3125Citations (PDF)
85An RCOR1 loss–associated gene expression signature identifies a prognostically significant DLBCL subgroup
Blood, 2015, 125, 959-966
4.226Citations (PDF)
86IDH2 R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma
Blood, 2015, 126, 1741-1752
4.2220Citations (PDF)
87Global microRNA expression profiling uncovers molecular markers for classification and prognosis in aggressive B-cell lymphoma
Blood, 2015, 125, 1137-1145
4.2123Citations (PDF)
88Genetic inactivation of TRAF3 in canine and human B-cell lymphoma
Blood, 2015, 125, 999-1005
4.278Citations (PDF)
89Cell of origin of transformed follicular lymphoma
Blood, 2015, 126, 2118-2127
4.2112Citations (PDF)
90Gray zone lymphoma with features intermediate between classicalHodgkin lymphoma and diffuse largeB‐cell lymphoma:Characteristics, outcomes, and prognostication among a large multicenter cohort
American Journal of Hematology, 2015, 90, 778-783
6.579Citations (PDF)
91A phase II trial of RCHOP followed by radioimmunotherapy for early stage (stages I/II) diffuse large B‐cell non‐Hodgkin lymphoma: ECOG3402
British Journal of Haematology, 2015, 170, 679-686
2.721Citations (PDF)
92Evaluation of the International Prognostic Score (IPS‐7) and a Simpler Prognostic Score (IPS‐3) for advanced Hodgkin lymphoma in the modern era
British Journal of Haematology, 2015, 171, 530-538
2.770Citations (PDF)
93Identification of Primary Mediastinal Large B-cell Lymphoma at Nonmediastinal Sites by Gene Expression Profiling
American Journal of Surgical Pathology, 2015, 39, 1322-1330
3.568Citations (PDF)
94Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types
Journal of the National Cancer Institute, 2015, 107, djv279
4.6167Citations (PDF)
95XIV. The pathology of transformation of indolent B cell lymphomas
Hematological Oncology, 2015, 33, 75-79
2.118Citations (PDF)
96Array comparative genomic hybridization reveals similarities between nodular lymphocyte predominant Hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma
British Journal of Haematology, 2015, 169, 415-422
2.775Citations (PDF)
97Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity
Blood, 2015, 125, 22-32
4.2508Citations (PDF)
98Outcome of Patients With Non-Hodgkin Lymphomas With Concurrent MYC and BCL2 Rearrangements Treated With CODOX-M/IVAC With Rituximab Followed by Hematopoietic Stem Cell Transplantation
Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 341-348
1.043Citations (PDF)
99Comprehensive miRNA sequence analysis reveals survival differences in diffuse large B-cell lymphoma patients
Genome Biology, 2015, 16,
12.2116Citations (PDF)
100Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry
Lancet Oncology, The, 2015, 16, 1111-1122
27.4581Citations (PDF)
101IL10 receptor is a novel therapeutic target in DLBCLs
Leukemia, 2015, 29, 1684-1694
7.767Citations (PDF)
102Summary and Future Directions
Seminars in Hematology, 2015, 52, 143-147
3.10Citations (PDF)
103The Prognostic Impact of CD163-Positive Macrophages in Follicular Lymphoma: A Study from the BC Cancer Agency and the Lymphoma Study Association
Clinical Cancer Research, 2015, 21, 3428-3435
6.8113Citations (PDF)
104Response‐adapted therapy for aggressive non‐Hodgkin's lymphomas based on early [18F] FDG‐PET scanning: ECOG‐ACRIN Cancer Research Group study (E3404)
British Journal of Haematology, 2015, 170, 56-65
2.753Citations (PDF)
105Outcomes in splenic marginal zone lymphoma: analysis of 107 patients treated in British Columbia
British Journal of Haematology, 2015, 169, 520-527
2.762Citations (PDF)
106Survival of human lymphoma cells requires B-cell receptor engagement by self-antigens
Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 13447-13454
7.5183Citations (PDF)
107Lifetime Physical Activity and the Risk of Non-Hodgkin Lymphoma
Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 873-877
1.112Citations (PDF)
108Outcome of patients with primary refractory diffuse large B cell lymphoma after R-CHOP treatment
Annals of Hematology, 2015, 94, 1839-1843
1.580Citations (PDF)
109The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development
Nature Medicine, 2015, 21, 1199-1208
33.0424Citations (PDF)
110Bromodomain Inhibition in Diffuse Large B-cell Lymphoma—Giving MYC a Brake
Clinical Cancer Research, 2015, 21, 4-6
6.819Citations (PDF)
111Comprehensive MYC and BCL2 Genetic Profiling in De Novo Diffuse Large B-Cell Lymphoma Demonstrates Clinically Relevant Genetic Alterations According to Cell of Origin Subtype
Blood, 2015, 126, 109-109
4.21Citations (PDF)
112Outcome of Observation As Initial Strategy in Patients with Mantle Cell Lymphoma
Blood, 2015, 126, 2699-2699
4.23Citations (PDF)
113A Clinicogenetic Risk Model (m7-FLIPI) Prospectively Identifies One-Half of Patients with Early Disease Progression of Follicular Lymphoma after First-Line Immunochemotherapy
Blood, 2015, 126, 333-333
4.29Citations (PDF)
114Disruptive ARID1A Mutations in Follicular Lymphoma Impair DNA Repair Efficiency and Are Associated with Favorable Outcome in Patients Receiving First-Line Immunochemotherapy
Blood, 2015, 126, 571-571
4.21Citations (PDF)
115Whole Exome Sequencing of Type 1 and Type 2 Enteropathy-Associated T Cell Lymphoma Reveals Genetic Basis of Eatl Oncogenesis
Blood, 2015, 126, 575-575
4.24Citations (PDF)
116Advanced Stage Classical Hodgkin Lymphoma Patients with a Negative PET-Scan Following Treatment with ABVD Have Excellent Outcomes without the Need for Consolidative Radiotherapy Regardless of Disease Bulk at Presentation
Blood, 2015, 126, 579-579
4.221Citations (PDF)
117Maintenance Rituximab Following R-CHOP Chemotherapy in Patients with Composite or Discordant, Indolent and Aggressive, B-Cell Non-Hodgkin Lymphomas
Blood, 2015, 126, 3950-3950
4.20Citations (PDF)
118A Chromatin Reader That Acts As a Key to Lock in and Coordinate Recruitment of Transcription Factors and a Novel Polycomb Complex to Bivalent Chromatin Thus Driving Formation of Germinal Centers and B-Cell Lymphomas
Blood, 2015, 126, 434-434
4.20Citations (PDF)
119Mass Cytometry Based Classification of Inter- and Intra-Tumoral Heterogeneity in Diffuse Large B-Cell Lymphoma
Blood, 2015, 126, 3908-3908
4.20Citations (PDF)
120Outcomes in Adolescents and Young Adults (AYA) with Hodgkin Lymphoma (HL) Treated on US Cooperative Group Protocols: An Adult Intergroup (E2496) and Children's Oncology Group (COG AHOD0031) Comparative Analysis
Blood, 2015, 126, 2636-2636
4.22Citations (PDF)
121Initial Therapy for Mantle Cell Lymphoma with Abbreviated R-CHOP Followed By Y90-Ibritumomab Tiuxetan: Ten Year Follow-up of the Phase 2 ECOG-ACRIN Study E1499
Blood, 2015, 126, 2702-2702
4.20Citations (PDF)
122Flow Cytometric Characterization of 129 Cases of Peripheral T Cell Lymphoma Not Otherwise Specified (PTCL NOS) and Angioimmunoblastic T Cell Lymphoma (AITL)
Blood, 2015, 126, 2667-2667
4.22Citations (PDF)
123Prevalence and Prognostic Value of BCL2 and MYC Protein Expression within ABC and GCB Subtypes in Patients with Previously Untreated, Diffuse Large B-Cell Lymphoma: Analysis from the Phase III MAIN Study
Blood, 2015, 126, 3971-3971
4.20Citations (PDF)
124Genetic Alterations of Gα13 Signaling Pathway with BCL2 over-Expression Confers Lymphoma Dissemination and Inferior Outcome in Germinal Center B Cell Diffuse Large B Cell Lymphoma
Blood, 2015, 126, 111-111
4.20Citations (PDF)
125Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404)
Leukemia and Lymphoma, 2014, 55, 768-772
1.448Citations (PDF)
126Loss of signalling via Gα13 in germinal centre B-cell-derived lymphoma
Nature, 2014, 516, 254-258
37.9285Citations (PDF)
127Diagnostic Accuracy of a Defined Immunophenotypic and Molecular Genetic Approach for Peripheral T/NK-cell Lymphomas
American Journal of Surgical Pathology, 2014, 38, 768-775
3.551Citations (PDF)
128FOXO1 repression contributes to block of plasma cell differentiation in classical Hodgkin lymphoma
Blood, 2014, 124, 3118-3129
4.241Citations (PDF)
129The role of body mass index in survival outcome for lymphoma patients: US intergroup experience
Annals of Oncology, 2014, 25, 669-674
10.044Citations (PDF)
130Essential Role of the Linear Ubiquitin Chain Assembly Complex in Lymphoma Revealed by Rare Germline Polymorphisms
Cancer Discovery, 2014, 4, 480-493
25.1139Citations (PDF)
131Duodenal follicular lymphoma: Comprehensive gene expression analysis with insights into pathogenesis
Cancer Science, 2014, 105, 608-615
3.964Citations (PDF)
132CD30 expression in de novo diffuse large B‐cell lymphoma: a population‐based study from British Columbia
British Journal of Haematology, 2014, 167, 608-617
2.792Citations (PDF)
133Etiologic Heterogeneity Among Non-Hodgkin Lymphoma Subtypes: The InterLymph Non-Hodgkin Lymphoma Subtypes Project
Journal of the National Cancer Institute Monographs, 2014, 2014, 130-144
1.7300Citations (PDF)
134Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma
Nature Genetics, 2014, 46, 329-335
25.2195Citations (PDF)
135An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era
Blood, 2014, 123, 837-842
4.2815Citations (PDF)
136MYC and BCL2 protein expression predicts survival in patients with diffuse large B‐cell lymphoma treated with rituximab
British Journal of Haematology, 2014, 165, 382-391
2.7165Citations (PDF)
137The tumour microenvironment in B cell lymphomas
Nature Reviews Cancer, 2014, 14, 517-534
60.8484Citations (PDF)
138BCL2 antibodies targeted at different epitopes detect varying levels of protein expression and correlate with frequent gene amplification in diffuse large B-cell lymphoma
Human Pathology, 2014, 45, 2144-2153
2.338Citations (PDF)
139A transgenic mouse model demonstrating the oncogenic role of mutations in the polycomb-group gene EZH2 in lymphomagenesis
Blood, 2014, 123, 3914-3924
4.275Citations (PDF)
140Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma
Blood, 2014, 123, 1681-1690
4.2123Citations (PDF)
141Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes
Blood, 2014, 123, 1699-1708
4.298Citations (PDF)
142Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405)
Blood, 2014, 123, 1665-1673
4.263Citations (PDF)
143Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma
Blood, 2014, 123, 2915-2923
4.2495Citations (PDF)
144Advanced-stage nodular lymphocyte predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: a matched pair outcome analysis
Blood, 2014, 123, 3567-3573
4.284Citations (PDF)
145High-resolution chromatin immunoprecipitation (ChIP) sequencing reveals novel binding targets and prognostic role for SOX11 in mantle cell lymphoma
Oncogene, 2014, 34, 1231-1240
6.565Citations (PDF)
146Cell-of-Origin Assignment in Diffuse Large B-Cell Lymphoma Determined By Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Has Prognostic Significance Independent of IPI and MYC/BCL2 Immunohistochemistry
Blood, 2014, 124, 1624-1624
4.21Citations (PDF)
147CD28 Mutations in Peripheral T-Cell Lymphomagenesis and Progression
Blood, 2014, 124, 1681-1681
4.25Citations (PDF)
148Single Cell Mass Cytometry for Phenotypic Analysis of Diffuse Large B-Cell Lymphoma
Blood, 2014, 124, 2976-2976
4.21Citations (PDF)
149Accurate Diagnosis of Aggressive B Cell Non-Hodgkin Lymphomas Using Gene Expression Profiling of Formalin-Fixed, Paraffin-Embedded Tissues
Blood, 2014, 124, 3016-3016
4.210Citations (PDF)
150FAS Mutations Accelerate Lymphoma Growth and Induce Therapeutic Resistance
Blood, 2014, 124, 3018-3018
4.21Citations (PDF)
151Outcome in Unselected Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Following R-CHOP When Stem Cell Transplantation Is Not Feasible
Blood, 2014, 124, 3069-3069
4.28Citations (PDF)
152Phase 2 Trial of Interim PET Scan-Tailored Therapy in Patients with Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL) in British Columbia (BC)
Blood, 2014, 124, 392-392
4.225Citations (PDF)
153Validation of a Prognostic Model to Assess the Risk of CNS Disease in Patients with Aggressive B-Cell Lymphoma
Blood, 2014, 124, 394-394
4.228Citations (PDF)
154The Impact of Concurrent MYC BCL2 Protein Expression on the Risk of Secondary Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma (DLBCL)
Blood, 2014, 124, 495-495
4.28Citations (PDF)
155A Phase 2/3 Multicenter, Randomized Study Comparing the Efficacy and Safety of Lenalidomide Versus Investigator’s Choice in Relapsed/Refractory DLBCL
Blood, 2014, 124, 628-628
4.218Citations (PDF)
156Clinical Significance of Genetic Aberrations in Diffuse Large B Cell Lymphoma
Blood, 2014, 124, 703-703
4.25Citations (PDF)
157Analysis of Relapse Biopsies in Classical Hodgkin Lymphoma Reveals Correlations with Outcome after Autologous Stem Cell Transplantation
Blood, 2014, 124, 136-136
4.20Citations (PDF)
158Chemical Genomics Reveals JAK STAT Activation As a Mechanism of Resistance to HDAC Inhibitors in B Cell Lymphomas
Blood, 2014, 124, 271-271
4.21Citations (PDF)
159Gray Zone Lymphoma (GZL) with Features Intermediate Between Classical Hodgkin Lymphoma (cHL) and Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of Tumor Immunophenotype (IP) and Critical Examination of Therapy with Associated Impact on Outcome
Blood, 2014, 124, 1703-1703
4.20Citations (PDF)
160Genetic Alterations of the MHC Class II Transactivator CIITA Are Frequent in Primary Mediastinal Large B-Cell Lymphoma and Associated with Diminished MHC Class II Expression
Blood, 2014, 124, 3040-3040
4.21Citations (PDF)
161Cell-of-Origin Subtype Classification of Diffuse Large B-Cell Lymphoma Using the Lymph2Cx Assay Retains Relevance in the Context of BCL2 and MYC Expression Status
Blood, 2014, 124, 1667-1667
4.20Citations (PDF)
162Primary Cutaneous Anaplastic Large Cell Lymphoma: The British Columbia Cancer Agency Experience
Blood, 2014, 124, 3076-3076
4.20Citations (PDF)
163Macrophages in T cell/histiocyte rich large B cell lymphoma strongly express metal-binding proteins and show a bi-activated phenotype
International Journal of Cancer, 2013, , n/a-n/a
4.327Citations (PDF)
164Newly Identified Mechanisms in B-Cell Non-Hodgkin Lymphomas Uncovered by Next-Generation Sequencing
Seminars in Hematology, 2013, 50, 303-313
3.117Citations (PDF)
165Lymphotoxin network pathways shape the tumor microenvironment
Current Opinion in Immunology, 2013, 25, 222-229
5.228Citations (PDF)
166MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
Blood, 2013, 121, 4021-4031
4.2655Citations (PDF)
167Controversies in BMT for Lymphoma
Biology of Blood and Marrow Transplantation, 2013, 19, S26-S32
1.65Citations (PDF)
168Analysis of FOXO1 mutations in diffuse large B-cell lymphoma
Blood, 2013, 121, 3666-3674
4.2157Citations (PDF)
169The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496
British Journal of Haematology, 2013, 161, 76-86
2.7132Citations (PDF)
170Genome‐wide methylation analyses identify a subset of mantle cell lymphoma with a high number of methylated CpGs and aggressive clinicopathological features
International Journal of Cancer, 2013, 133, 2852-2863
4.316Citations (PDF)
171EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation
Cancer Cell, 2013, 23, 677-692
33.0813Citations (PDF)
172Mechanism-Based Epigenetic Chemosensitization Therapy of Diffuse Large B-Cell Lymphoma
Cancer Discovery, 2013, 3, 1002-1019
25.1205Citations (PDF)
173Aberration in DNA Methylation in B-Cell Lymphomas Has a Complex Origin and Increases with Disease Severity
PLoS Genetics, 2013, 9, e1003137
3.2113Citations (PDF)
174Related F-box proteins control cell death in Caenorhabditis elegans and human lymphoma
Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 3943-3948
7.572Citations (PDF)
175Incidence of transformation to aggressive lymphoma in limited-stage follicular lymphoma treated with radiotherapy
Annals of Oncology, 2013, 24, 428-432
10.042Citations (PDF)
176Next-generation Sequencing Discoveries in Lymphoma
Advances in Anatomic Pathology, 2013, 20, 110-116
2.316Citations (PDF)
177Colorimetric In Situ Hybridization Identifies MYC Gene Signal Clusters Correlating With Increased Copy Number, mRNA, and Protein in Diffuse Large B-Cell Lymphoma
American Journal of Clinical Pathology, 2013, 139, 242-254
0.732Citations (PDF)
178Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial
Blood, 2013, 121, 3547-3553
4.2133Citations (PDF)
179Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing
Blood, 2013, 122, 1256-1265
4.2376Citations (PDF)
180Sex- and Subtype-Specific Analysis of H2AFX Polymorphisms in Non-Hodgkin Lymphoma
PLoS ONE, 2013, 8, e74619
2.33Citations (PDF)
181Nodular Lymphocyte Predominant Hodgkin Lymphoma and T Cell/Histiocyte Rich Large B Cell Lymphoma - Endpoints of a Spectrum of One Disease?
PLoS ONE, 2013, 8, e78812
2.3108Citations (PDF)
182Reciprocal expression of the endocytic protein HIP1R and its repressor FOXP1 predicts outcome in R-CHOP-treated diffuse large B-cell lymphoma patients
Leukemia, 2013, 28, 362-372
7.729Citations (PDF)
183Pharmacological and genomic profiling identifies NF-κB–targeted treatment strategies for mantle cell lymphoma
Nature Medicine, 2013, 20, 87-92
33.0328Citations (PDF)
184Outcome Of Patients With Double-Hit Lymphomas Treated With CODOX-M/IVAC + R Followed By Hematopoietic Stem Cell Transplantation In British Columbia
Blood, 2013, 122, 1788-1788
4.25Citations (PDF)
185The Role Of Body Mass Index In Survival Outcome For Lymphoma Patients: US Intergroup Experience
Blood, 2013, 122, 3060-3060
4.25Citations (PDF)
186Evaluation Of a Novel 3 Factor Prognostic Score (PS-3) For Patients With Advanced Hodgkin Lymphoma (HL) Treated On US Intergroup E2496
Blood, 2013, 122, 4277-4277
4.23Citations (PDF)
187Gemcitabine, Dexamethasone, and Cisplatin (GDP) As Secondary Chemotherapy In Relapsed/Refractory Peripheral T-Cell Lymphoma
Blood, 2013, 122, 4345-4345
4.25Citations (PDF)
188Specific KIR and HLA Genotypes Affect Outcomes Of Single-Agent Anti-CD20 Immunotherapy Of Follicular Lymphoma
Blood, 2013, 122, 507-507
4.25Citations (PDF)
189Genomic Rearrangements Involving Programmed Death Ligands Are Recurrent In Primary Mediastinal Large B-Cell Lymphoma
Blood, 2013, 122, 635-635
4.23Citations (PDF)
190Non-Hodgkin Lymphoma Risk and Variants in Genes Controlling Lymphocyte Development
PLoS ONE, 2013, 8, e75170
2.310Citations (PDF)
191Characterization Of The Effects Of Mutated EZH2 On Expression and Epigenome In a Mouse Lymphoma Model
Blood, 2013, 122, 346-346
4.20Citations (PDF)
192Predicting Cell Of Origin In Diffuse Large B-Cell Lymphoma By High Dimensional Flow Cytometry
Blood, 2013, 122, 4301-4301
4.20Citations (PDF)
193Genetic Alterations In Immune Cell Crosstalk Genes In Diffuse Large B-Cell Lymphoma Predict Survival
Blood, 2013, 122, 500-500
4.20Citations (PDF)
194Outcomes In Splenic Marginal Zone Lymphoma: Analysis Of 108 Patients Treated In British Columbia (BC)
Blood, 2013, 122, 4369-4369
4.20Citations (PDF)
195The Outcome Of Patients With Post Transplant and Immunodeficiency Associated Lymphoproliferative Disorder: The BCCA Experience
Blood, 2013, 122, 4390-4390
4.20Citations (PDF)
196Characterizing The CpG Methylation Of Epstein-Barr Virus DNA In The Plasma Of Patients With Hodgkin Lymphoma and HIV-Associated Burkitt Lymphoma
Blood, 2013, 122, 4232-4232
4.20Citations (PDF)
197Molecular and Functional Characterization Of The Novel Protein-Coding Gene Tihl (Translocated in Hodgkin’s Lymphoma) in Hematopoiesis
Blood, 2013, 122, 3680-3680
4.20Citations (PDF)
198Impact of Time from Diagnosis to Initiation of Curative-Intent Chemotherapy on Clinical Outcomes in Patients with Hodgkin Lymphoma
Blood, 2013, 122, 4237-4237
4.23Citations (PDF)
199Determining Cell-Of-Origin Subtypes In Diffuse Large B-Cell Lymphoma Using Gene Expression Profiling On Formalin-Fixed Paraffin-Embedded Tissue – An L.L.M.P.P. Project
Blood, 2013, 122, 73-73
4.20Citations (PDF)
200Protein Tyrosine Phosphatase Type-1 (PTPN1) Is Frequently Mutated In Primary Mediastinal B Cell Lymphoma and Hodgkin Lymphoma
Blood, 2013, 122, 242-242
4.21Citations (PDF)
201Improved Risk Stratification With Addition Of Male Sex (S) To The Elderly International Prognostic Index (S-EIPI) For DLBCL Patients &gt; 60 Years Treated With R-CHOP: An International Collaboration Of The US Intergroup, German High-Grade Non-Hodgkin Lymphoma Study Group and Groupe d’Etude De Lymphome d’Adultes
Blood, 2013, 122, 3045-3045
4.22Citations (PDF)
202The Use Of GDP (Gemcitabine, Dexamethasone and Cisplatin) in The Primary Therapy Of Peripheral T-Cell Lymphomas
Blood, 2013, 122, 1804-1804
4.20Citations (PDF)
203Gray Zone Lymphoma (GZL) With Features Intermediate Between Classical Hodgkin Lymphoma (cHL) and Diffuse Large B-Cell Lymphoma (DLBCL): A Large Retrospective Multicenter Analysis Of Clinical Characteristics, Treatment, Outcomes, and Prognosis In The Current Era
Blood, 2013, 122, 847-847
4.22Citations (PDF)
204Automated Analysis of Multidimensional Flow Cytometry Data Improves Diagnostic Accuracy Between Mantle Cell Lymphoma and Small Lymphocytic Lymphoma
American Journal of Clinical Pathology, 2012, 137, 75-85
0.739Citations (PDF)
205Gene expression profiling of microdissected Hodgkin Reed-Sternberg cells correlates with treatment outcome in classical Hodgkin lymphoma
Blood, 2012, 120, 3530-3540
4.2133Citations (PDF)
206Pathogenesis of follicular lymphoma
Journal of Clinical Investigation, 2012, 122, 3424-3431
10.6278Citations (PDF)
207FOXO1 is a tumor suppressor in classical Hodgkin lymphoma
Blood, 2012, 119, 3503-3511
4.2159Citations (PDF)
208Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma
Blood, 2012, 119, 1963-1971
4.2333Citations (PDF)
209A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies
Blood, 2012, 119, 5118-5125
4.2148Citations (PDF)
210Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial
Blood, 2012, 120, 3280-3287
4.2194Citations (PDF)
211B Cells With High Side Scatter Parameter by Flow Cytometry Correlate With Inferior Survival in Diffuse Large B-Cell Lymphoma
American Journal of Clinical Pathology, 2012, 137, 805-814
0.712Citations (PDF)
212MALT1 Small Molecule Inhibitors Specifically Suppress ABC-DLBCL In Vitro and In Vivo
Cancer Cell, 2012, 22, 812-824
33.0263Citations (PDF)
213Molecular distinctions between pediatric and adult mature B-cell non-Hodgkin lymphomas identified through genomic profiling
Blood, 2012, 119, 3757-3766
4.278Citations (PDF)
214A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma
Blood, 2012, 120, 2290-2296
4.256Citations (PDF)
215Galectin-3 binds to CD45 on diffuse large B-cell lymphoma cells to regulate susceptibility to cell death
Blood, 2012, 120, 4635-4644
4.295Citations (PDF)
216Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics
Nature, 2012, 490, 116-120
37.9834Citations (PDF)
217Genome-wide miRNA profiling of mantle cell lymphoma reveals a distinct subgroup with poor prognosis
Blood, 2012, 119, 4939-4948
4.2101Citations (PDF)
218Limited‐stage diffuse large B‐cell lymphoma treated with abbreviated systemic therapy and consolidation radiotherapy
Cancer, 2012, 118, 4156-4165
4.049Citations (PDF)
219CD80 (B7.1) is expressed on both malignant B cells and nonmalignant stromal cells in non‐Hodgkin lymphoma
Cytometry Part B - Clinical Cytometry, 2012, 82B, 112-119
1.623Citations (PDF)
220Mature Results From ECOG Study E1405 – A Phase II Study of VcR-CVAD with Maintenance Rituximab for Previously Untreated Mantle Cell Lymphoma
Blood, 2012, 120, 153-153
4.29Citations (PDF)
221The Outcome of Advanced Stage Nodular Lymphocyte Predominant Hodgkin's Lymphoma (NLPHL) Compared to Classical Hodgkin's Lymphoma (CHL): A Matched Pair Analysis
Blood, 2012, 120, 1531-1531
4.26Citations (PDF)
222CD30 Expression in Diffuse Large B-Cell Lymphoma
Blood, 2012, 120, 1558-1558
4.25Citations (PDF)
223CSF1R Inhibition by PLX3397 in Patients with Relapsed or Refractory Hodgkin Lymphoma: Results From a Phase 2 Single Agent Clinical Trial
Blood, 2012, 120, 1638-1638
4.223Citations (PDF)
224A Phase II Trial of R-CHOP Followed by Zevalin Radioimmunotherapy for Patients with Previously Untreated Stages I and II CD20+ Diffuse Large Cell Non-Hodgkin's Lymphoma: an Eastern Cooperative Oncology Group Study (E3402).
Blood, 2012, 120, 2687-2687
4.22Citations (PDF)
225The Outcome of Primary Mediastinal Large B-Cell Lymphoma (PMBCL) in the R-CHOP Treatment Era
Blood, 2012, 120, 303-303
4.235Citations (PDF)
226Gene Expression Signatures That Delineate Biologic and Prognostic Subgroups in Peripheral T-Cell Lymphoma
Blood, 2012, 120, 679-679
4.22Citations (PDF)
227Response-Adapted Therapy for Diffuse Large B-Cell Non-Hodgkin's Lymphoma (DLBCL)Based On Early [18F] FDG-PET Scanning: An Eastern Cooperative Oncology Group Study (E3404)
Blood, 2012, 120, 687-687
4.24Citations (PDF)
228Genetic Variation in Cell Death Genes and Risk of Non-Hodgkin Lymphoma
PLoS ONE, 2012, 7, e31560
2.325Citations (PDF)
229Mutations of STAT6 DNA Binding Domain Are Characteristic of PMBL and Belong to the Genetic Signature of This Entity.
Blood, 2012, 120, 2645-2645
4.20Citations (PDF)
230High Incidence of EZH2 Mutations with Variable Mutation Load in Follicular Lymphoma and Its Consequences for EZH2 Targeted Therapy
Blood, 2012, 120, 545-545
4.20Citations (PDF)
231A 7-Gene Microrna Signature Characteristic of Mantle Cell Lymphoma Reveals Focal Adhesion and Integrin Signalling, Proteasome-Mediated Degradation, and the PI3K Signalling Cascade As Important to MCL Pathogenesis
Blood, 2012, 120, 1586-1586
4.20Citations (PDF)
232Quality of Life Results From Eastern Cooperative Oncology Group Protocol E4402 (RESORT): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Indolent Non-Hodgkin's Lymphoma
Blood, 2012, 120, 235-235
4.20Citations (PDF)
233Population Survey of Mantle Cell Lymphoma (MCL) in British Columbia (BC) – A Heterogeneous Disorder with Improved Outcomes in the Modern Era
Blood, 2012, 120, 1602-1602
4.20Citations (PDF)
234SOX11 Directly Represses Wnt/β-Catenin Signaling and Identifies a Subgroup of Mantle Cell Lymphoma Patients with Improved Survival with Intensive Treatment
Blood, 2012, 120, 895-895
4.23Citations (PDF)
235Identification of a Novel Protein-Coding Gene (TIHL) and Its Functional Relevance in Myeloid Cells.
Blood, 2012, 120, 2333-2333
4.20Citations (PDF)
236FAS Mutations Are Associated with Therapeutic Resistance in Follicular Lymphoma
Blood, 2012, 120, 1549-1549
4.20Citations (PDF)
237Genetic Abnormalities in Follicular Lymphoma and Transformed Follicular Lymphoma.
Blood, 2012, 120, 2648-2648
4.20Citations (PDF)
238Differences in Outcomes in Males and Females with Diffuse Large B-Cell Lymphoma with Induction Rituximab and Follicular Lymphoma Treated with Maintenance Rituximab
Blood, 2012, 120, 3705-3705
4.20Citations (PDF)
239Diagnostic Accuracy of a Defined Immunophenotypic and Molecular Genetic Approach for Peripheral T/NK-Cell Lymphomas: A North American PTCL Study Group Project
Blood, 2012, 120, 1545-1545
4.26Citations (PDF)
240Tumor-Associated Macrophages Predict Outcome in Follicular Lymphoma
Blood, 2012, 120, 682-682
4.24Citations (PDF)
241Large-Scale High Resolution Integration of Copy Number and Gene Expression in DLBCL Reveals Focal and Frequent Deletions in Chromatin Modifying Genes with Outcome Correlation
Blood, 2012, 120, 295-295
4.20Citations (PDF)
242Next-Generation Sequencing of Lymphoid Cancers: From Discovery to Clinical Translation
Blood, 2012, 120, SCI-12-SCI-12
4.20Citations (PDF)
243Mantle cell lymphoma: report of the 2010 Mantle Cell Lymphoma Consortium Workshop
Leukemia and Lymphoma, 2011, 52, 24-33
1.422Citations (PDF)
244Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome
Blood, 2011, 118, 4585-4590
4.285Citations (PDF)
245Molecular Pathogenesis of Hodgkin's Lymphoma: Increasing Evidence of the Importance of the Microenvironment
Journal of Clinical Oncology, 2011, 29, 1812-1826
16.9369Citations (PDF)
246Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma
Nature, 2011, 476, 298-303
37.91,539Citations (PDF)
247Transformation of follicular lymphoma
Best Practice and Research in Clinical Haematology, 2011, 24, 147-163
1.7153Citations (PDF)
248Molecular Characteristics of Mantle Cell Lymphoma Presenting With Clonal Plasma Cell Component
American Journal of Surgical Pathology, 2011, 35, 177-189
3.524Citations (PDF)
249MYC and Aggressive B-cell Lymphomas
Advances in Anatomic Pathology, 2011, 18, 219-228
2.3138Citations (PDF)
250Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome
Blood, 2011, 117, 1595-1604
4.2185Citations (PDF)
251Peripheral T-cell lymphoma
Blood, 2011, 117, 6756-6767
4.2296Citations (PDF)
252Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation
Blood, 2011, 117, 2451-2459
4.2593Citations (PDF)
253Enteropathy-associated T-cell lymphoma: clinical and histological findings from the International Peripheral T-Cell Lymphoma Project
Blood, 2011, 118, 148-155
4.2348Citations (PDF)
254Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium
Blood, 2011, 117, 7070-7078
4.2179Citations (PDF)
255The molecular pathogenesis of primary mediastinal large B-cell lymphoma
Blood, 2011, 118, 2659-2669
4.2203Citations (PDF)
256MicroRNA profiles of t(14;18)–negative follicular lymphoma support a late germinal center B-cell phenotype
Blood, 2011, 118, 5550-5558
4.282Citations (PDF)
257MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers
Nature, 2011, 471, 377-381
37.9595Citations (PDF)
258Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment
Blood, 2011, 118, 1350-1358
4.2184Citations (PDF)
259Loss of BAF250a (ARID1A) is frequent in high‐grade endometrial carcinomas
Journal of Pathology, 2011, 224, 328-333
4.9223Citations (PDF)
260Follicular non-Hodgkin lymphoma grades 3A and 3B have a similar outcome and appear incurable with anthracycline-based therapy
Annals of Oncology, 2011, 22, 1164-1169
10.067Citations (PDF)
261The Stromal Cell Marker SPARC Predicts for Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab
American Journal of Clinical Pathology, 2011, 135, 54-61
0.776Citations (PDF)
262MicroRNAs Are Independent Predictors of Outcome in Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP
Clinical Cancer Research, 2011, 17, 4125-4135
6.8131Citations (PDF)
263Accurate Classification of Diffuse Large B-Cell Lymphoma into Germinal Center and Activated B-Cell Subtypes Using a Nuclease Protection Assay on Formalin-Fixed, Paraffin-Embedded Tissues
Clinical Cancer Research, 2011, 17, 3727-3732
6.868Citations (PDF)
264Impact of Concordant and Discordant Bone Marrow Involvement on Outcome in Diffuse Large B-Cell Lymphoma Treated With R-CHOP
Journal of Clinical Oncology, 2011, 29, 1452-1457
16.9207Citations (PDF)
265BCL2 Predicts Survival in Germinal Center B-cell–like Diffuse Large B-cell Lymphoma Treated with CHOP-like Therapy and Rituximab
Clinical Cancer Research, 2011, 17, 7785-7795
6.8163Citations (PDF)
266Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project
Blood, 2011, 117, 3402-3408
4.2412Citations (PDF)
267Gray zone lymphoma: chromosomal aberrations with immunophenotypic and clinical correlations
Modern Pathology, 2011, 24, 1586-1597
4.8144Citations (PDF)
268BCL2 mutations in diffuse large B-cell lymphoma
Leukemia, 2011, 26, 1383-1390
7.7144Citations (PDF)
269Patterns of Failure in Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma (HL) Treated with ABVD + Radiotherapy or the Stanford V Regimen in the Randomized Phase III North American Intergroup Trial: E2496
Blood, 2011, 118, 1603-1603
4.23Citations (PDF)
270Mutated EZH2 Collaborates with Myc in Inducing Lymphoma in a Mouse Model
Blood, 2011, 118, 227-227
4.23Citations (PDF)
271A Gene Expression Signature in Diagnostic Formalin Fixed Paraffin Embedded Tissue Predicts Overall Survival in Locally Advanced and Advanced Stage Classical Hodgkin Lymphoma – a Correlative Study From the E2496 Intergroup Trial
Blood, 2011, 118, 430-430
4.21Citations (PDF)
272Diffuse Large B-Cell Lymphoma with Testicular Involvement: Outcome and Risk of CNS Relapse in the Rituximab Era
Blood, 2011, 118, 780-780
4.23Citations (PDF)
273Survival of Peripheral T-Cell Lymphomas (PTCLs) Patients Following Relapse: Spectrum of Disease and Rare Long-Term Survivors
Blood, 2011, 118, 96-96
4.22Citations (PDF)
274CSF1R Expression of Hodgkin Reed Sternberg Cells Is Associated with the Number of Macrophages in the Tumor Microenvironment and Is Correlated with Treatment Outcome
Blood, 2011, 118, 427-427
4.20Citations (PDF)
275Recurrent Oncogenic Mutations in CCND3 in Aggressive Lymphomas
Blood, 2011, 118, 435-435
4.21Citations (PDF)
276Gene Risk Scores Based on Expression of 6 Genes Quanitated by Nuclease Protection Assay in Formalin Fixed Paraffin-Embedded Tissue (FFPET) Specimens From CHOP and RCHOP Treated Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Predict Outcome: An ECOG and SWOG Study
Blood, 2011, 118, 87-87
4.21Citations (PDF)
277Epigenetic Profiling of Primary DLBCLs Reveals Novel DNA Methylation-Based Clusters and New Underlying Mechanisms of Lymphomagenesis
Blood, 2011, 118, 556-556
4.20Citations (PDF)
278High-Resolution Chromatin Immunoprecipitation (ChIP) Sequencing Identifies Novel Binding Targets and Prognostic Role for SOX11 in Mantle Cell Lymphoma
Blood, 2011, 118, 585-585
4.20Citations (PDF)
279Inactivating Gene Alterations of MHC Class II Transactivator CIITA Are Recurrent in Primary Mediastinal B Cell Lymphoma and Hodgkin Lymphoma
Blood, 2011, 118, 437-437
4.24Citations (PDF)
280The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation
Blood, 2010, 115, 289-295
4.2179Citations (PDF)
281Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study
Blood, 2010, 115, 775-777
4.2120Citations (PDF)
282Genome-wide copy number analysis of Hodgkin Reed-Sternberg cells identifies recurrent imbalances with correlations to treatment outcome
Blood, 2010, 116, 418-427
4.2165Citations (PDF)
283Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling
Blood, 2010, 116, 953-961
4.2128Citations (PDF)
284EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis
Blood, 2010, 116, 5247-5255
4.2289Citations (PDF)
285DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma
Blood, 2010, 116, e81-e89
4.2145Citations (PDF)
286Immunoexpression of Survivin in non-neoplastic lymphoid tissues and malignant lymphomas using a new monoclonal antibody reactive on paraffin sections
Journal of Hematopathology, 2010, 3, 3-9
0.44Citations (PDF)
287Cooperative Epigenetic Modulation by Cancer Amplicon Genes
Cancer Cell, 2010, 18, 590-605
33.0274Citations (PDF)
288High resolution analysis of follicular lymphoma genomes reveals somatic recurrent sites of copy‐neutral loss of heterozygosity and copy number alterations that target single genes
Genes Chromosomes and Cancer, 2010, 49, 669-681
3.051Citations (PDF)
289Long‐term outcomes for patients with limited stage follicular lymphoma
Cancer, 2010, 116, 3797-3806
4.0109Citations (PDF)
290GBV‐C/hepatitis G virus infection and non‐Hodgkin lymphoma: a case control study
International Journal of Cancer, 2010, 126, 2885-2892
4.358Citations (PDF)
291Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (R‐CHOP)
British Journal of Haematology, 2010, 148, 235-244
2.740Citations (PDF)
292Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B‐cell lymphoma treated with R‐CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E‐IPI)
British Journal of Haematology, 2010, 151, 143-151
2.791Citations (PDF)
293Selective ablation of the YxxM motif of IL-7Rα suppresses lymphomagenesis but maintains lymphocyte development
Oncogene, 2010, 29, 3854-3864
6.516Citations (PDF)
294Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
Nature, 2010, 463, 88-92
37.91,540Citations (PDF)
295Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin
Nature Genetics, 2010, 42, 181-185
25.21,599Citations (PDF)
296HVCN1 modulates BCR signal strength via regulation of BCR-dependent generation of reactive oxygen species
Nature Immunology, 2010, 11, 265-272
23.6220Citations (PDF)
297Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy
Annals of Oncology, 2010, 21, 1046-1052
10.0194Citations (PDF)
298Acquired TNFRSF14 Mutations in Follicular Lymphoma Are Associated with Worse Prognosis
Cancer Research, 2010, 70, 9166-9174
3.8178Citations (PDF)
299Expression of p21 Protein Predicts Clinical Outcome in DLBCL Patients Older than 60 Years Treated with R-CHOP but not CHOP: A Prospective ECOG and Southwest Oncology Group Correlative Study on E4494
Clinical Cancer Research, 2010, 16, 2435-2442
6.827Citations (PDF)
300Prognostic biomarkers in malignant lymphomas
Leukemia and Lymphoma, 2010, 51, 11-19
1.421Citations (PDF)
301Constitutively overexpressed 21 kDa protein in Hodgkin lymphoma and aggressive non-Hodgkin lymphomas identified as cytochrome B5b (CYB5B)
Molecular Cancer, 2010, 9,
29.216Citations (PDF)
302A Novel Method of Amplification of FFPET-Derived RNA Enables Accurate Disease Classification with Microarrays
Journal of Molecular Diagnostics, 2010, 12, 680-686
2.552Citations (PDF)
303Tumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma
New England Journal of Medicine, 2010, 362, 875-885
34.61,214Citations (PDF)
304Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma
Cell, 2010, 142, 699-713
33.71,025Citations (PDF)
305Prognostic Factors in Follicular Lymphoma
Journal of Clinical Oncology, 2010, 28, 2902-2913
16.9143Citations (PDF)
306Prognostic implications of extranodal involvement in patients with diffuse large B-cell lymphoma treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone
Leukemia and Lymphoma, 2010, 51, 1-10
1.461Citations (PDF)
307Oncogenically active MYD88 mutations in human lymphoma
Nature, 2010, 470, 115-119
37.91,409Citations (PDF)
308BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy
Journal of Clinical Investigation, 2010, 120, 4569-4582
10.6108Citations (PDF)
309Gemcitabine, Dexamethasone, and Cisplatin (GDP) Is An Effective and Well-Tolerated out-Patient Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Hodgkin Lymphoma (HL)
Blood, 2010, 116, 113-113
4.216Citations (PDF)
310Outcome of Patients with Chemotherapy Refractory and Early Progressive Diffuse Large B Cell Lymphoma After R-CHOP Treatment
Blood, 2010, 116, 1751-1751
4.24Citations (PDF)
311Incorporation of ABVD Increases Cure Rates of Patients with Limited Stage Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL)
Blood, 2010, 116, 3887-3887
4.22Citations (PDF)
312A Randomized Phase III Trial of ABVD Vs. Stanford V +/− Radiation Therapy In Locally Extensive and Advanced Stage Hodgkin's Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperatve Oncology Group (E2496)
Blood, 2010, 116, 415-415
4.218Citations (PDF)
313Randomized Phase III Trial Comparing ABVD + Radiotherapy and the Stanford V Regimen In Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the US Intergroup Trial E2496
Blood, 2010, 116, 416-416
4.28Citations (PDF)
314Hodgkin Lymphoma Patients with Stage II B or Stage II Bulky Disease Have Advanced Disease and Should Not Be Included In Limited Stage Trials
Blood, 2010, 116, 417-417
4.22Citations (PDF)
315Mutations In MLL2 and MEF2B Genes In Follicular Lymphoma and Diffuse Large B-Cell Lymphoma
Blood, 2010, 116, 473-473
4.26Citations (PDF)
316Identification of Genes Frequently Mutated In FL and DLBCL with Transcriptome, Genome and Exome Sequencing
Blood, 2010, 116, 804-804
4.21Citations (PDF)
317FDG-PET Scan Guided Consolidative Radiation Therapy Optimizes Outcome In Patients with Advanced-Stage Diffuse Large B-Cell Lymphoma (DLBCL) with Residual Abnormalities on CT Scan Following R-CHOP
Blood, 2010, 116, 854-854
4.29Citations (PDF)
318Concurrent BCL2 and MYC Protein Expression by Immunohistochemistry Determines Clinical Outcome In DLBCL Patients Treated with R-CHOP
Blood, 2010, 116, 2005-2005
4.22Citations (PDF)
319The Prognosis of Limited Stage Peripheral T-Cell Lymphoma (PTCL): A Population-Based Analysis and Comparison to Diffuse Large B-Cell Lymphoma (DLBCL)
Blood, 2010, 116, 4129-4129
4.20Citations (PDF)
320Comparing MicroRNA Expression In Aggressive and Indolent Non-Hodgkin Lymphomas Identifies a Prognostic Signature for Mantle Cell Lymphoma
Blood, 2010, 116, 800-800
4.20Citations (PDF)
321Recurrent DNA Mutations In Non-Hodgkin Lymphomas Reveal Candidate Therapeutic Targets
Blood, 2010, 116, 632-632
4.20Citations (PDF)
322Front-Line Therapy with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) Followed by 2 Years of Rituximab Maintenance for Follicular Lymphoma (FL) Is Associated with Excellent Outcomes and Improved Progression-Free Survival (PFS) In Comparison to No Maintenance
Blood, 2010, 116, 1803-1803
4.20Citations (PDF)
323Prediction of Survival In Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes Reflecting Tumor and Microenvironment
Blood, 2010, 116, 2006-2006
4.20Citations (PDF)
324Model-based clustering of array CGH data
Bioinformatics, 2009, 25, i30-i38
4.717Citations (PDF)
325The International Prognostic Index predicts outcome in aggressive adult T-cell leukemia/lymphoma: analysis of 126 patients from the International Peripheral T-cell Lymphoma Project
Annals of Oncology, 2009, 20, 715-721
10.057Citations (PDF)
326Genetic variation in the NBS1, MRE11, RAD50 and BLM genes and susceptibility to non-Hodgkin lymphoma
BMC Medical Genetics, 2009, 10,
1.828Citations (PDF)
327The significance of TP53 in lymphoid malignancies: mutation prevalence, regulation, prognostic impact and potential as a therapeutic target
British Journal of Haematology, 2009, 146, 257-269
2.759Citations (PDF)
328Array-based DNA methylation profiling in follicular lymphoma
Leukemia, 2009, 23, 1858-1866
7.771Citations (PDF)
329Biomarkers and Prognosis in Malignant Lymphomas
Clinical Lymphoma and Myeloma, 2009, 9, 160-166
1.87Citations (PDF)
330Atypical Lymphoid Hyperplasia Mimicking Lymphoma
Hematology/Oncology Clinics of North America, 2009, 23, 729-745
2.252Citations (PDF)
331MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy
Blood, 2009, 114, 3533-3537
4.2595Citations (PDF)
332Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations
Blood, 2009, 114, 826-834
4.2188Citations (PDF)
333Decreased major histocompatibility complex class II expression in diffuse large B-cell lymphoma does not correlate with CpG methylation of class II transactivator promoters III and IV
Leukemia and Lymphoma, 2009, 50, 1875-1878
1.49Citations (PDF)
334Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival
Blood, 2009, 114, 2273-2279
4.2560Citations (PDF)
335A New Immunostain Algorithm Classifies Diffuse Large B-Cell Lymphoma into Molecular Subtypes with High Accuracy
Clinical Cancer Research, 2009, 15, 5494-5502
6.8606Citations (PDF)
336Circos: An information aesthetic for comparative genomics
Genome Research, 2009, 19, 1639-1645
4.610,591Citations (PDF)
337Follicular Lymphoma of the Thyroid Gland
American Journal of Surgical Pathology, 2009, 33, 22-34
3.549Citations (PDF)
338Genome-wide profiling of follicular lymphoma by array comparative genomic hybridization reveals prognostically significant DNA copy number imbalances
Blood, 2009, 113, 137-148
4.2129Citations (PDF)
339Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival
Blood, 2009, 113, 3773-3780
4.2142Citations (PDF)
340Differentiation stage–specific expression of microRNAs in B lymphocytes and diffuse large B-cell lymphomas
Blood, 2009, 113, 3754-3764
4.2233Citations (PDF)
341The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL
Blood, 2009, 113, 5536-5548
4.2225Citations (PDF)
342Stem cells in Hodgkin lymphoma?
Blood, 2009, 113, 5694-5694
4.23Citations (PDF)
343Interaction between organochlorines and the AHR gene, and risk of non-Hodgkin lymphoma
Cancer Causes and Control, 2009, 21, 11-22
1.736Citations (PDF)
344HLA-DR Protein Expression Correlates with Non-Neoplastic T-Cell Infiltration and Predicts Survival in Patients with Primary Mediastinal Large B Cell Lymphoma (PMBCL) Treated with CHOP Chemotherapy.
Blood, 2009, 114, 133-133
4.23Citations (PDF)
345Tyrosine 641 of the EZH2 Oncogene Is Frequently Mutated in Follicular and Diffuse Large B-Cell Lymphomas of Germinal Center Origin.
Blood, 2009, 114, 139-139
4.23Citations (PDF)
346The International Prognostic Factor Project Score (IPS) in Advanced Stage Hodgkin Lymphoma Has Limited Utility in Patients Treated in the Modern Era.
Blood, 2009, 114, 1554-1554
4.24Citations (PDF)
347The VcR-CVAD Regimen Produces a High Complete Response Rate in Untreated Mantle Cell Lymphoma (MCL): First Analysis of E1405 – A Phase II Study of VcR-CVAD with Maintenance Rituximab for MCL.
Blood, 2009, 114, 1661-1661
4.29Citations (PDF)
348A Comparison of Gene Expression Pattern in Major Histocompatibility Class II-Low Diffuse Large B-Cell Lymphoma with Plasmablastic Lymphoma.
Blood, 2009, 114, 1941-1941
4.21Citations (PDF)
349The Percentage of Cytotoxic T-Cells in Mantle Cell Lymphoma (MCL) Biopsies Predicts Response to Rituximab.
Blood, 2009, 114, 2923-2923
4.21Citations (PDF)
350Number of Lymphoma-Associated-Macrophages (LAM) Is An Independent Predictor of Survival in Patients with Mantle Cell Lymphoma (MCL).
Blood, 2009, 114, 3944-3944
4.22Citations (PDF)
351R-CHOP with Etoposide Substituted for Doxorubicin (R-CEOP): Excellent Outcome in Diffuse Large B Cell Lymphoma for Patients with a Contraindication to Anthracyclines.
Blood, 2009, 114, 408-408
4.231Citations (PDF)
352Base-Pair Resolution of Somatic and Germline-Derived Genome Rearrangement Breakpoints in Follicular Lymphoma.
Blood, 2009, 114, 439-439
4.20Citations (PDF)
353Gene Expression Profiling of Microdissected Hodgkin Reed Sternberg Cells: Molecular Subtypes and Treatment Outcome Correlations.
Blood, 2009, 114, 268-268
4.212Citations (PDF)
354Hypoxia Inducible Factor 1á (HIF-1á) Regulates CD20 Expression in Lymphoma Cells: Possible Implications for Rituximab Based Therapy in Diffuse Large B Cell Lymphoma (DLBCL).
Blood, 2009, 114, 1698-1698
4.22Citations (PDF)
355Accurate Classification of Diffuse Large B Cell Lymphoma Into Germinal Center and Activated B Cell Subtypes Using a Nuclease Protection Assay On Formalin Fixed Paraffin Embedded Tissue: A Study From the Lymphoma and Leukemia Molecular Profiling Project.
Blood, 2009, 114, 620-620
4.20Citations (PDF)
356MicroRNA Are Useful Biomarkers for Prediction of Response to Therapy and Survival of Patients with Diffuse Large B-Cell Lymphoma.
Blood, 2009, 114, 624-624
4.21Citations (PDF)
357TNFRSF14 Is Mutated in a Subset of Follicular Lymphoma and Correlated with Inferior Prognosis.
Blood, 2009, 114, 1919-1919
4.21Citations (PDF)
358Prediction of Survival in Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes: Integration of Tumor and Microenvironment Contributions.
Blood, 2009, 114, 622-622
4.22Citations (PDF)
359MYC Translocations and Expression Are Clinically Important in R-CHOP Treated Patients with De Novo DLBCL.
Blood, 2009, 114, 1100-1100
4.20Citations (PDF)
360Chromosomal Alterations in Gene Expression-Defined Pediatric Aggressive B-Cell Non-Hodgkin Lymphoma (B-NHL).
Blood, 2009, 114, 2922-2922
4.20Citations (PDF)
361ABC and GCB DLBCLs Display Unique Biologically Distinct and Clinically Relevant Epigenetic Signatures.
Blood, 2009, 114, 619-619
4.210Citations (PDF)
362Bortezomib Added to CVP-R Is Safe and Effective for Previously Untreated Advanced Stage Follicular Lymphoma: A Phase II Study by the NCIC Clinical Trials Group.
Blood, 2009, 114, 407-407
4.21Citations (PDF)
363High Microvascular Density Correlates with Poor Outcome in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Rituximab Plus Chemotherapy (R-CT).
Blood, 2009, 114, 1948-1948
4.20Citations (PDF)
364Hepatitis C virus and risk of non‐Hodgkin lymphoma in British Columbia, Canada
International Journal of Cancer, 2008, 122, 630-633
4.327Citations (PDF)
365Prognostic significance of secondary cytogenetic alterations in follicular lymphomas
Genes Chromosomes and Cancer, 2008, 47, 1038-1048
3.050Citations (PDF)
366Allogeneic SCT for relapsed composite and transformed lymphoma using related and unrelated donors: long-term results
Bone Marrow Transplantation, 2008, 42, 601-608
2.321Citations (PDF)
367Genomic profiling reveals different genetic aberrations in systemic ALK‐positive and ALK‐negative anaplastic large cell lymphomas
British Journal of Haematology, 2008, 140, 516-526
2.7149Citations (PDF)
368Cytogenetic abnormalities and clinical correlations in peripheral T‐cell lymphoma
British Journal of Haematology, 2008, 141, 461-469
2.7106Citations (PDF)
369Constitutive overexpression of a novel 21 kDa protein by Hodgkin Lymphoma and Aggressive Non-Hodgkin Lymphomas
Molecular Cancer, 2008, 7, 12
29.26Citations (PDF)
370Classification of Non-Hodgkin's Lymphoma
Hematology/Oncology Clinics of North America, 2008, 22, 781-805
2.220Citations (PDF)
371Involved-Nodal Radiation Therapy As a Component of Combination Therapy for Limited-Stage Hodgkin's Lymphoma: A Question of Field Size
Journal of Clinical Oncology, 2008, 26, 5170-5174
16.9138Citations (PDF)
372Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways
Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 13520-13525
7.5916Citations (PDF)
373Population-Based Analysis of Incidence and Outcome of Transformed Non-Hodgkin's Lymphoma
Journal of Clinical Oncology, 2008, 26, 5165-5169
16.9359Citations (PDF)
374Impact of whole genome amplification on analysis of copy number variants
Nucleic Acids Research, 2008, 36, e80-e80
15.576Citations (PDF)
375Stromal Gene Signatures in Large-B-Cell Lymphomas
New England Journal of Medicine, 2008, 359, 2313-2323
34.61,687Citations (PDF)
376LMO2 Protein Expression Predicts Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Based Chemotherapy With and Without Rituximab
Journal of Clinical Oncology, 2008, 26, 447-454
16.9165Citations (PDF)
377Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-κB pathways in subtypes of diffuse large B-cell lymphoma
Blood, 2008, 111, 3701-3713
4.2342Citations (PDF)
378Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study
Blood, 2008, 112, 3088-3098
4.2190Citations (PDF)
379ALK− anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project
Blood, 2008, 111, 5496-5504
4.2832Citations (PDF)
380Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP
Blood, 2008, 111, 5509-5514
4.296Citations (PDF)
381Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP
Blood, 2008, 112, 3425-3433
4.2132Citations (PDF)
382Comparison of Outcome Between Refractory/Relapsed De Novo Diffuse Large B-Cell and Transformed Lymphoma Using Related and Unrelated Allogeneic Hematopoietic SCT.
Blood, 2008, 112, 2173-2173
4.22Citations (PDF)
383Interim Positron Emission Tomography (PET) in Diffuse Large B-Cell Lymphoma: Independent Expert Nuclear Medicine Evaluation of ECOG 3404
Blood, 2008, 112, 372-372
4.23Citations (PDF)
384Follicular Non-Hodgkin Lymphoma Grade 3a and 3b Subtypes Exhibit Similar Clinical Behaviour and Treatment Outcome
Blood, 2008, 112, 3777-3777
4.25Citations (PDF)
385Autologous Stem Cell Transplantation Is Superior to Myeloablative Allogeneic SCT as a Salvage Therapy for Patients with Refractory/Relapsed Transformed Lymphoma
Blood, 2008, 112, 4459-4459
4.28Citations (PDF)
386Deletion in Chromosome 17p12 and Gains in Chromosome 9q33.3 by Array Comparative Hybridization Are Associated with R-CHOP Treatment Failure in Patients with Diffuse Large B Cell Lymphoma
Blood, 2008, 112, 477-477
4.22Citations (PDF)
387Expression of Hypoxia-Inducible Factor (HIF) Is An Independent Favorable Prognostic Factor in Diffuse Large B-Cell Lymphoma (DLBCL) Treated with R-CHOP
Blood, 2008, 112, 479-479
4.22Citations (PDF)
388Array-CGH Identifies Both Common and Subtype-Specific Genomic Aberrations in Marginal Zone Lymphomas
Blood, 2008, 112, 622-622
4.21Citations (PDF)
389The Voltage-Gated Proton Channel HVCN1 Co-Localizes with B Cell Receptor and Is Involved in Class Switch Recombination in Vivo
Blood, 2008, 112, 707-707
4.24Citations (PDF)
390Salvage Therapy with Allogeneic Stem Cell Transplantation Results in Better Outcome for Patients with Relapsed/Refractory Follicular Lymphoma Compared to Those with Transformed Non-Hodgkin Lymphoma: A Population-Based Comparative Study.
Blood, 2008, 112, 975-975
4.229Citations (PDF)
391Loss of CIITA and MHC Class II Expression in Diffuse Large B-Cell Lymphoma Is Not Explained by Methylation of CIITA Promoters III and IV.
Blood, 2008, 112, 1786-1786
4.20Citations (PDF)
392Molecular Signatures Implicate Innate Immune Cells, Fibrosis, and Angiogenesis in Survival Following R-CHOP Treatment of Diffuse Large B Cell Lymphoma
Blood, 2008, 112, 475-475
4.21Citations (PDF)
393Genetic Abnormalities Involved in the Development and Progression of Follicular Lymphoma.
Blood, 2008, 112, 2049-2049
4.20Citations (PDF)
394Genetic Alterations Detected by High-Resolution Array Comparative Genomic Hybridization in Microdissected HRS Cells Correlate with Treatment Outcome in Classical Hodgkin Lymphoma
Blood, 2008, 112, 522-522
4.21Citations (PDF)
395Combined FOXP3+ and PD1+ T Cell Density and Architectural Patterns Predict Overall Survival and Risk of Transformation in Uniformly Treated Patients with Follicular Lymphoma
Blood, 2008, 112, 2815-2815
4.22Citations (PDF)
396Genome-Wide Expression Profiling Predicts Treatment Outcome in Classical Hodgkin Lymphoma
Blood, 2008, 112, 520-520
4.20Citations (PDF)
397High Prevalence of TERT Mutations in Chronic Lymphocytic Leukemia
Blood, 2008, 112, 3126-3126
4.21Citations (PDF)
398Prognostic Significance of BCL6 Translocation in Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP
Blood, 2008, 112, 3782-3782
4.20Citations (PDF)
399Lymphomas with Concurrent T(14;18) and 8q24 Translocations Are Under- Reported and Clinical Outcome Depends on the MYC Partner
Blood, 2008, 112, 804-804
4.20Citations (PDF)
400Genetic Variation in H2AFX Contributes to Risk of Non–Hodgkin Lymphoma
Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 1098-1106
1.138Citations (PDF)
401Specific Secondary Genetic Alterations in Mantle Cell Lymphoma Provide Prognostic Information Independent of the Gene Expression–Based Proliferation Signature
Journal of Clinical Oncology, 2007, 25, 1216-1222
16.9170Citations (PDF)
402Primary therapy for adults with T-cell lymphoblastic lymphoma with hematopoietic stem-cell transplantation results in favorable outcomes
Annals of Oncology, 2007, 18, 535-540
10.072Citations (PDF)
403Phase II study of denileukin diftitox for previously treated indolent non-Hodgkin lymphoma: Final results of E1497
Leukemia and Lymphoma, 2007, 48, 2397-2402
1.423Citations (PDF)
404CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma
Leukemia and Lymphoma, 2007, 48, 1102-1109
1.462Citations (PDF)
405HLA-DR protein status predicts survival in patients with diffuse large B-cell lymphoma treated on the MACOP-B chemotherapy regimen
Leukemia and Lymphoma, 2007, 48, 542-546
1.445Citations (PDF)
406Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell–like diffuse large B cell lymphoma
Journal of Experimental Medicine, 2007, 204, 633-643
9.2188Citations (PDF)
407A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150
Annals of Oncology, 2007, 18, 116-121
10.0151Citations (PDF)
408Immunohistochemical Prognostic Markers in Diffuse Large B-Cell Lymphoma: Validation of Tissue Microarray As a Prerequisite for Broad Clinical Applications—A Study From the Lunenburg Lymphoma Biomarker Consortium
Journal of Clinical Oncology, 2007, 25, 805-812
16.9276Citations (PDF)
409The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP
Blood, 2007, 109, 1857-1861
4.21,322Citations (PDF)
410Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival
Blood, 2007, 109, 4599-4606
4.2246Citations (PDF)
411Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma
Blood, 2007, 110, 4396-4405
4.2105Citations (PDF)
412Expression of TRAF1 and Nuclear c-Rel Distinguishes Primary Mediastinal Large Cell Lymphoma From Other Types of Diffuse Large B-cell Lymphoma
American Journal of Surgical Pathology, 2007, 31, 106-112
3.580Citations (PDF)
413Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma
Leukemia, 2007, 21, 2332-2343
7.7206Citations (PDF)
414A clinicopathological retrospective study of 131 patients with primary bone lymphoma: a population-based study of successively treated cohorts from the British Columbia Cancer Agency
Annals of Oncology, 2007, 18, 129-135
10.0205Citations (PDF)
415Whole-Genome Analysis and HLA Genotyping of Enteropathy-Type T-Cell Lymphoma Reveals 2 Distinct Lymphoma Subtypes
Gastroenterology, 2007, 132, 1902-1911
0.9249Citations (PDF)
416A systematic evaluation of the ataxia telangiectasia mutated gene does not show an association with non‐Hodgkin lymphoma
International Journal of Cancer, 2007, 121, 1967-1975
4.38Citations (PDF)
417Organochlorines and risk of non‐Hodgkin lymphoma
International Journal of Cancer, 2007, 121, 2767-2775
4.3122Citations (PDF)
418Frequent occurrence of deletions in primary mediastinal B‐cell lymphoma
Genes Chromosomes and Cancer, 2007, 46, 1090-1097
3.038Citations (PDF)
419A comprehensive genetic and histopathologic analysis identifies two subgroups of B-cell malignancies carrying a t(14;19)(q32;q13) or variant BCL3-translocation
Leukemia, 2007, 21, 1532-1544
7.790Citations (PDF)
420Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms
British Journal of Haematology, 2007, 136, 286-293
2.7149Citations (PDF)
421Allogeneic Stem Cell Transplantation as Treatment for Relapsed and High-Risk Peripheral T-Cell Lymphoma.
Blood, 2007, 110, 3040-3040
4.22Citations (PDF)
422Preliminary Pharmacokinetic (PK) Analysis of Eastern Cooperative Oncology Group Protocol E4402: Rituximab Extended Schedule or Re-Treatment Trial (RESORT).
Blood, 2007, 110, 3420-3420
4.214Citations (PDF)
423Gene Expression Signatures Predict Overall Survial in Diffuse Large B Cell Lymphoma Treated with Rituximab and Chop-Like Chemotherapy.
Blood, 2007, 110, 348-348
4.211Citations (PDF)
424The Architecural Pattern of FOXP3+ T Cells Predicts Risk of Transformation in Patients with Follicular Lymphoma (FL).
Blood, 2007, 110, 358-358
4.23Citations (PDF)
425Phase II Study of R-CHOP Followed by 90Y-Ibritumomab Tiuxetan in Untreated Mantle Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499.
Blood, 2007, 110, 389-389
4.235Citations (PDF)
426LMO2 Protein Expression Predicts Survival in Patients with Diffuse Large B-Cell Lymphoma in the Pre- and Post-Rituximab Treatment Eras.
Blood, 2007, 110, 52-52
4.22Citations (PDF)
427CARD11 as an Oncogene in Diffuse Large B Cell Lymphoma.
Blood, 2007, 110, 692-692
4.22Citations (PDF)
428Addition of Rituximab to CHOP Chemotherapy Significantly Improves Survival of Patients with Transformed Lymphoma.
Blood, 2007, 110, 790-790
4.214Citations (PDF)
429Both Discordant and Concordant Bone Marrow (BM) Involvement Predict for a Poorer Outcome Independent of the IPI in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with R-CHOP.
Blood, 2007, 110, 1559-1559
4.21Citations (PDF)
430High Frequency of 1p36.32 Deletion or Loss of Heterozygosity in Follicular Lymphoma (FL).
Blood, 2007, 110, 183-183
4.21Citations (PDF)
431Prognostic Utility of Extranodal Disease Involvement in Diffuse Large B-Cell Lymphoma in Patients Treated with R-CHOP.
Blood, 2007, 110, 1563-1563
4.20Citations (PDF)
432CD20 Mutations at the Rituximab Binding Site Are Rare and Are Not a Significant Cause of R-CHOP Resistance in Patients with De Novo Diffuse Large B-Cell Lymphoma.
Blood, 2007, 110, 686-686
4.22Citations (PDF)
433Distinct Genetic Aberrations in Molecular Subtypes of Diffuse Large B Cell Lymphoma Detected by Array CGH.
Blood, 2007, 110, 2631-2631
4.22Citations (PDF)
434Follicular Lymphomas with and without Translocation t(14;18) Differ in Gene Expression Profiles and Genetic Alterations.
Blood, 2007, 110, 360-360
4.27Citations (PDF)
435Gene Expression Model of Survival and Transformation in Follicular Lymphoma (FL): A Study by the LLMPP.
Blood, 2007, 110, 2606-2606
4.20Citations (PDF)
436Major Histocompatibility Class II (MHCII) and Germinal Center Associated Gene Expression Correlate with Overall Survival in Ritiximab and CHOP-Like Treated Diffuse Large B Cell Lymphoma (DLBCL) Patients Using Formalin Fixed Paraffin Embedded (FFPE) Tissues.
Blood, 2007, 110, 50-50
4.21Citations (PDF)
437Vascularization Predicts Overall Survival (OS) & Risk of Transformation (RT) in Uniformly Treated Patients with Follicular Lymphoma (FL).
Blood, 2007, 110, 184-184
4.20Citations (PDF)
438Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions
Blood, 2006, 107, 1101-1107
4.271Citations (PDF)
439The Role of Hepatitis C Virus Infection and Non-Hodgkin Lymphoma in Canada
American Journal of Epidemiology, 2006, 163, S89-S89
3.30Citations (PDF)
440Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study
Blood, 2006, 107, 4207-4213
4.2251Citations (PDF)
441Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival
Blood, 2006, 108, 311-318
4.2115Citations (PDF)
442Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial
Blood, 2006, 108, 3295-3301
4.2566Citations (PDF)
443Haematopoietic stem cell transplantation as primary therapy of sporadic adult Burkitt lymphoma*
British Journal of Haematology, 2006, 133, 634-637
2.728Citations (PDF)
444The BCL11AXL transcription factor: its distribution in normal and malignant tissues and use as a marker for plasmacytoid dendritic cells
Leukemia, 2006, 20, 1439-1441
7.748Citations (PDF)
445Four human t(11;14)(q13;q32)-containing cell lines having classic and variant features of Mantle Cell Lymphoma
Leukemia Research, 2006, 30, 449-457
0.730Citations (PDF)
446Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma
Journal of Clinical Oncology, 2006, 24, 3121-3127
16.91,270Citations (PDF)
447BCL2 Expression Is a Prognostic Marker for the Activated B-Cell–Like Type of Diffuse Large B-Cell Lymphoma
Journal of Clinical Oncology, 2006, 24, 961-968
16.9292Citations (PDF)
448Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience
Annals of Oncology, 2006, 17, 123-130
10.0230Citations (PDF)
449Molecular Diagnosis of Burkitt's Lymphoma
New England Journal of Medicine, 2006, 354, 2431-2442
34.6860Citations (PDF)
450Mutation and genomic deletion status of ataxia telangiectasia mutated ( ATM ) and p53 confer specific gene expression profiles in mantle cell lymphoma
Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 2352-2357
7.5147Citations (PDF)
451High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver
Blood, 2005, 106, 1473-1478
4.2117Citations (PDF)
452Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL)
Blood, 2005, 106, 2169-2174
4.2438Citations (PDF)
453Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling
Blood, 2005, 106, 4315-4321
4.2338Citations (PDF)
454Aggressive B-cell lymphomas: a review based on the workshop of the XI Meeting of the European Association for Haematopathology
Histopathology, 2005, 46, 241-255
3.629Citations (PDF)
455Incidence and spectrum of non-Hodgkin lymphoma in Chinese migrants to British Columbia
British Journal of Haematology, 2005, 128, 792-796
2.738Citations (PDF)
456Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma*
British Journal of Haematology, 2005, 131, 223-230
2.780Citations (PDF)
457Concurrent translocation of BCL2 and MYC with a single immunoglobulin locus in high-grade B-cell lymphomas
Leukemia, 2005, 19, 659-663
7.742Citations (PDF)
458Expression pattern of intracellular leukocyte-associated proteins in primary mediastinal B cell lymphoma
Leukemia, 2005, 19, 856-861
7.725Citations (PDF)
459ALK-positive diffuse large B-cell lymphoma with ALK-Clathrin fusion belongs to the spectrum of pediatric lymphomas
Leukemia, 2005, 19, 1839-1840
7.742Citations (PDF)
460Amplification ofIGH/MYC fusion in clinically aggressiveIGH/BCL2-positive germinal center B-cell lymphomas
Genes Chromosomes and Cancer, 2005, 43, 414-423
3.042Citations (PDF)
461The treatment of primary central nervous system lymphoma in 122 immunocompetent patients
Cancer, 2005, 103, 1008-1017
4.048Citations (PDF)
462Introduction of Combined CHOP Plus Rituximab Therapy Dramatically Improved Outcome of Diffuse Large B-Cell Lymphoma in British Columbia
Journal of Clinical Oncology, 2005, 23, 5027-5033
16.9916Citations (PDF)
463Validation of tissue microarray immunohistochemistry staining and interpretation in diffuse large B-cell lymphoma
Leukemia and Lymphoma, 2005, 46, 693-701
1.453Citations (PDF)
464Molecular Pathogenesis of Mucosa-Associated Lymphoid Tissue Lymphoma
Journal of Clinical Oncology, 2005, 23, 6370-6378
16.9176Citations (PDF)
465Hematopathology Approaches to Diagnosis and Prognosis of Indolent B-Cell Lymphomas
Hematology American Society of Hematology Education Program, 2005, 2005, 299-306
2.86Citations (PDF)
466High-Dose Therapy and Autologous Hematopoietic Stem-Cell Transplantation Does Not Increase the Risk of Second Neoplasms for Patients With Hodgkin's Lymphoma: A Comparison of Conventional Therapy Alone Versus Conventional Therapy Followed by Autologous Hematopoietic Stem-Cell Transplantation
Journal of Clinical Oncology, 2005, 23, 7994-8002
16.962Citations (PDF)
467Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction
Blood, 2005, 106, 3183-3190
4.2355Citations (PDF)
468Primary paranasal sinus lymphoma: natural history and improved outcome with central nervous system chemoprophylaxis
Leukemia and Lymphoma, 2005, 46, 1721-1727
1.455Citations (PDF)
469Mantle cell lymphoma in the ocular adnexal region
Ophthalmology, 2005, 112, 114-119
7.892Citations (PDF)
470Helicobacter pylori and MALT Lymphoma
Gastroenterology, 2005, 128, 1579-1605
0.9200Citations (PDF)
471Expression of the FOXP1 Transcription Factor Is Strongly Associated with Inferior Survival in Patients with Diffuse Large B-Cell Lymphoma
Clinical Cancer Research, 2005, 11, 1065-1072
6.8143Citations (PDF)
472Hodgkin’s lymphoma in Chinese migrants to British Columbia:a 25-year survey
Annals of Oncology, 2004, 15, 626-630
10.038Citations (PDF)
473Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification
Annals of Oncology, 2004, 15, 1467-1475
10.0335Citations (PDF)
474Low-Grade Lymphoma
Hematology American Society of Hematology Education Program, 2004, 2004, 203-220
2.847Citations (PDF)
475Long-term disease-free survival of patients with advanced follicular lymphoma after allogeneic bone marrow transplantation
British Journal of Haematology, 2004, 127, 311-321
2.746Citations (PDF)
476Establishment of a novel anaplastic large-cell lymphoma-cell line (COST) from a ‘small-cell variant’ of ALCL
Leukemia, 2004, 18, 1693-1698
7.733Citations (PDF)
477Centrosome abnormalities in ALK-positive anaplastic large-cell lymphoma
Leukemia, 2004, 18, 1910-1911
7.723Citations (PDF)
478Molecular Signatures of Lymphoma
International Journal of Hematology, 2004, 80, 401-409
1.513Citations (PDF)
479Identification of cytogenetic subgroups and karyotypic pathways of clonal evolution in follicular lymphomas
Genes Chromosomes and Cancer, 2004, 39, 195-204
3.0115Citations (PDF)
480Delineation of a minimal region of deletion at 6q16.3 in follicular lymphoma and construction of a bacterial artificial chromosome contig spanning a 6-megabase region of 6q16-q21
Genes Chromosomes and Cancer, 2004, 40, 60-65
3.026Citations (PDF)
481Improved Outcome of Human Immunodeficiency Virus-Associated Plasmablastic Lymphoma of the Oral Cavity in the Era of Highly Active Antiretroviral Therapy: A Report of Two Cases
Leukemia and Lymphoma, 2004, 45, 1881-1885
1.458Citations (PDF)
482Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
Blood, 2004, 103, 275-282
4.23,958Citations (PDF)
483The Spectrum of Lymphoma with 8q24 Aberrations: A Clinical, Pathological and Cytogenetic Study of 87 Consecutive Cases
Leukemia and Lymphoma, 2004, 45, 519-528
1.465Citations (PDF)
484Comprehensive whole genome array CGH profiling of mantle cell lymphoma model genomes
Human Molecular Genetics, 2004, 13, 1827-1837
2.9115Citations (PDF)
485Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells
New England Journal of Medicine, 2004, 351, 2159-2169
34.61,339Citations (PDF)
486BCL2 Translocation Defines a Unique Tumor Subset within the Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma
American Journal of Pathology, 2004, 165, 159-166
3.4271Citations (PDF)
487Emerging prognostic factors in diffuse large B cell lymphoma
Current Opinion in Oncology, 2004, 16, 436-441
2.139Citations (PDF)
488Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project
Blood, 2004, 103, 4251-4258
4.2317Citations (PDF)
489Characterization of the recurrent translocation t(1;1)(p36.3;q21.1-2) in non-Hodgkin lymphoma by multicolor banding and fluorescence in situ hybridization analysis
Genes Chromosomes and Cancer, 2003, 36, 375-381
3.030Citations (PDF)
490Non-muscle myosin heavy chain (MYH9): A new partner fused to ALK in anaplastic large cell lymphoma
Genes Chromosomes and Cancer, 2003, 37, 427-432
3.0133Citations (PDF)
491Follicular lymphoma lacking the t(14;18)(q32;q21): identification of two disease subtypes
British Journal of Haematology, 2003, 120, 424-433
2.7121Citations (PDF)
492Multicolour fluorescence in situ hybridization analysis of t(14;18)‐positive follicular lymphoma and correlation with gene expression data and clinical outcome
British Journal of Haematology, 2003, 122, 745-759
2.741Citations (PDF)
493Multicolor Karyotyping and Clinicopathological Analysis of Three Intravascular Lymphoma Cases
Modern Pathology, 2003, 16, 716-724
4.847Citations (PDF)
494Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma
Journal of Experimental Medicine, 2003, 198, 851-862
9.21,046Citations (PDF)
495Prominent intrasinusoidal infiltration of the bone marrow by mantle cell lymphoma
Human Pathology, 2003, 34, 789-791
2.317Citations (PDF)
496MALT1 is deregulated by both chromosomal translocation and amplification in B-cell non-Hodgkin lymphoma
Blood, 2003, 101, 4539-4546
4.2191Citations (PDF)
497Molecular Pathogenesis of Mucosal-Associated Lymphoid Tissue (MALT) Lymphoma
Leukemia and Lymphoma, 2003, 44, S13-S20
1.416Citations (PDF)
498ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases
Blood, 2003, 102, 2568-2573
4.2289Citations (PDF)
499Treatment of Elderly Hodgkin's Lymphoma Patients with a Novel 5-drug Regimen (ODBEP): A Phase II Study
Leukemia and Lymphoma, 2002, 43, 1395-1402
1.436Citations (PDF)
500Primary Cutaneous Diffuse Large B-Cell Lymphoma
American Journal of Clinical Pathology, 2002, 117, 574-580
0.746Citations (PDF)
501Establishment and comprehensive analysis of a new human transformed follicular lymphoma B cell line, Tat-1
Leukemia, 2002, 16, 276-283
7.710Citations (PDF)
502Cytogenetic Analysis in Mantle Cell Lymphoma: A Review of 214 Cases
Leukemia and Lymphoma, 2002, 43, 783-791
1.455Citations (PDF)
503Evidence for Early Infection of Nonneoplastic Natural Killer Cells by Epstein-Barr Virus
Journal of Virology, 2002, 76, 11139-11142
3.635Citations (PDF)
504Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma
Blood, 2002, 99, 618-626
4.2267Citations (PDF)
505The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
New England Journal of Medicine, 2002, 346, 1937-1947
34.63,634Citations (PDF)
506Brief Chemotherapy and Involved-Region Irradiation for Limited-Stage Diffuse Large-Cell Lymphoma: An 18-Year Experience From the British Columbia Cancer Agency
Journal of Clinical Oncology, 2002, 20, 197-204
16.9102Citations (PDF)
507Cytogenetic findings in reactive lymphoid hyperplasia: Significance of non-clonal t(3;14) and t(3;22)
American Journal of Hematology, 2002, 70, 133-138
6.511Citations (PDF)
508Uncovering novel inter- and intrachromosomal chromosome 1 aberrations in follicular lymphomas by using an innovative multicolor banding technique
Genes Chromosomes and Cancer, 2002, 34, 201-210
3.021Citations (PDF)
509Heavy multinodular cutaneous lymphoid infiltrates: clinicopathologic features and B-cell clonality
Journal of Cutaneous Pathology, 2002, 29, 159-167
1.129Citations (PDF)
510MALT Lymphomas
Hematology American Society of Hematology Education Program, 2001, 2001, 241-258
2.8136Citations (PDF)
511MCL1 transgenic mice exhibit a high incidence of B-cell lymphoma manifested as a spectrum of histologic subtypes
Blood, 2001, 97, 3902-3909
4.2169Citations (PDF)
512Cyclin D3 is a target gene of t(6;14)(p21.1;q32.3) of mature B-cell malignancies
Blood, 2001, 98, 2837-2844
4.2126Citations (PDF)
513Leukaemic infiltration of an adenocarcinoma effusion
British Journal of Haematology, 2001, 112, 257-257
2.70Citations (PDF)
514Analysis of secondary chromosomal alterations in 165 cases of follicular lymphoma with t(14;18)
Genes Chromosomes and Cancer, 2001, 30, 375-382
3.0143Citations (PDF)
515Systemic anaplastic large-cell lymphoma: Results from the non-Hodgkin's lymphoma classification project
American Journal of Hematology, 2001, 67, 172-178
6.547Citations (PDF)
516Therapeutic consequences of pathology and prognostic factors in aggressive NHL – Analysis of ALCL
Annals of Hematology, 2001, 80, B45-B48
1.53Citations (PDF)
517Involvement of the X chromosome in non-Hodgkin lymphoma
Genes Chromosomes and Cancer, 2000, 28, 246-257
3.040Citations (PDF)
518Allogeneic bone marrow transplantation for low-grade lymphoma and chronic lymphocytic leukemia
Bone Marrow Transplantation, 2000, 25, 605-612
2.367Citations (PDF)
519TNFR-Associated Factor Family Protein Expression in Normal Tissues and Lymphoid Malignancies
Journal of Immunology, 2000, 165, 5084-5096
0.6138Citations (PDF)
520Clinical Significance of the t(14;18) AndBCL2Overexpression in Follicular Large Cell Lymphoma
Leukemia and Lymphoma, 2000, 36, 513-523
1.423Citations (PDF)
521Lymphoma With Follicular and Monocytoid B-Cell Components
American Journal of Clinical Pathology, 2000, 114, 516-522
0.721Citations (PDF)
522Blastic Mantle Cell Leukemia: An Unusual Presentation of Blastic Mantle Cell Lymphoma
Modern Pathology, 2000, 13, 825-833
4.860Citations (PDF)
523Small Noncleaved, Non-Burkitt's (Burkitt-Like) Lymphoma: Cytogenetics Predict Outcome and Reflect Clinical Presentation
Journal of Clinical Oncology, 1999, 17, 1558-1558
16.9175Citations (PDF)
524Prognostic Significance of Anaplastic Lymphoma Kinase (ALK) Protein Expression in Adults With Anaplastic Large Cell Lymphoma
Blood, 1999, 93, 3913-3921
4.2475Citations (PDF)
525Concurrent chromosomal alterations at 3q27, 8q24 and 18q21 in B-cell lymphomas
British Journal of Haematology, 1999, 105, 437-440
2.733Citations (PDF)
526Anaplastic large cell lymphoma: a clinicopathologic analysis
1999, 17, 137-148
37Citations (PDF)
527Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation
Lancet, The, 1999, 354, 1698-1699
62.3116Citations (PDF)
528Bcl-6 and Bcl-2 protein expression in diffuse large B-cell lymphoma and follicular lymphoma: Correlation with 3q27 and 18q21 chromosomal abnormalities
Human Pathology, 1999, 30, 803-808
2.3127Citations (PDF)
529Primary non-Hodgkin's lymphoma and malakoplakia of the vagina: A case report
Human Pathology, 1999, 30, 871-874
2.317Citations (PDF)
530Lymphoproliferative disorders following allogeneic bone marrow transplantation: the Vancouver experience
Bone Marrow Transplantation, 1998, 22, 981-987
2.3102Citations (PDF)
531Clinicopathological Analysis of Follicular Lymphoma with a Polyploid Karyotype
Leukemia and Lymphoma, 1998, 28, 383-389
1.45Citations (PDF)
532Molecular Methods for Detecting t(11;14) Translocations in Mantle-Cell Lymphomas
Diagnostic Molecular Pathology, 1998, 7, 209-214
1.425Citations (PDF)
533Immunohistochemical Analysis of bc1–2, bax, mcl-1, and bc1-X Expression in Ovarian Surface Epithelial Tumors
International Journal of Gynecological Pathology, 1998, 17, 255-260
1.325Citations (PDF)
534Homozygous Deletions at Chromosome 9p21 Involving p16 and p15 Are Associated With Histologic Progression in Follicle Center Lymphoma
Blood, 1998, 91, 4677-4685
4.2160Citations (PDF)
535t(2;5) Positive Lymphoma with Peripheral Blood Involvement
Leukemia and Lymphoma, 1998, 28, 415-422
1.424Citations (PDF)
536Second Malignancies in Patients With Hairy Cell Leukemia in British Columbia: A 20-Year Experience
Blood, 1998, 92, 1160-1164
4.2107Citations (PDF)
537Clinical Utility of Heteroduplex Analysis of TCR Gamma Gene Rearrangements in the Diagnosis of T-Cell Lymphoproliferative Disorders
American Journal of Clinical Pathology, 1997, 108, 295-301
0.751Citations (PDF)
538Bone Marrow Involvement in T-Cell–Rich B-Cell Lymphoma
American Journal of Clinical Pathology, 1997, 108, 570-578
0.752Citations (PDF)
539PATHOLOGIC PROGNOSTIC FACTORS IN DIFFUSE AGGRESSIVE NON-HODGKIN'S LYMPHOMA
Hematology/Oncology Clinics of North America, 1997, 11, 847-862
2.223Citations (PDF)
540Mantle Cell Lymphoma: A Clinicopathologic Study of 80 Cases
Blood, 1997, 89, 2067-2078
4.2467Citations (PDF)
541Prognostic Significance of Bcl-2 Protein Expression and Bcl-2 Gene Rearrangement in Diffuse Aggressive Non-Hodgkin's Lymphoma
Blood, 1997, 90, 244-251
4.2459Citations (PDF)
542Immunohistochemical Analysis of Interleukin-1β–Converting Enzyme/Ced-3 Family Protease, CPP32/Yama/Caspase-3, in Hodgkin's Disease
Blood, 1997, 90, 2451-2455
4.232Citations (PDF)
543Prognostic Significance of Bax Protein Expression in Diffuse Aggressive Non-Hodgkin's Lymphoma
Blood, 1997, 90, 3173-3178
4.265Citations (PDF)
544Bcl-6and Lymphoproliferative Disorders
Leukemia and Lymphoma, 1997, 26, 515-525
1.47Citations (PDF)
545Spontaneous regression of chemotherapy-refractory non-hodgkin's lymphoma preceding the development of secondary leukaemia
Leukemia and Lymphoma, 1996, 20, 351-353
1.40Citations (PDF)
546Comparison of Cytogenetic Analysis, Southern Analysis, and Polymerase Chain Reaction for the Detection of t(14; 18) in Follicular Lymphoma
American Journal of Clinical Pathology, 1995, 103, 472-478
0.7211Citations (PDF)
547Frequent association of t(3;14) or variant with other lymphoma-specific translocations
British Journal of Haematology, 1995, 89, 569-575
2.732Citations (PDF)
548Acute Leukemia with Structural Rearrangements of Chromosome 3
Leukemia and Lymphoma, 1995, 16, 369-377
1.441Citations (PDF)
549Simultaneous Development of Diffuse Immunoblastic Lymphoma in Recipients of Renal Transplants From a Single Cadaver Donor: Transmission of Epstein-Barr Virus and Triggering by OKT3
American Journal of Kidney Diseases, 1994, 23, 130-134
1.418Citations (PDF)
550Clinical, haematological and cytogenetic features in 24 patients with structural rearrangements of the Q arm of chromosome 3
British Journal of Haematology, 1993, 83, 158-165
2.774Citations (PDF)
551Combination of t(14;18) and a Burkitt's Type Translocation in B-cell Malignancies
Leukemia and Lymphoma, 1993, 10, 433-441
1.475Citations (PDF)
552T-cell receptor variable region gene expression in cutaneous T-cell lymphomas
Journal of Cutaneous Pathology, 1992, 19, 21-26
1.118Citations (PDF)
553Histopathologic, immunophenotypic and genotypic analyses in ocular adnexal lymphoproliferative disorders
Australian and New Zealand Journal of Ophthalmology, 1992, 20, 247-251
0.57Citations (PDF)
554t(11;18)(q21;q21.1): A recurring translocation in lymphomas of mucosa-associated lymphoid tissue (malt)?
Genes Chromosomes and Cancer, 1992, 4, 183-187
3.0100Citations (PDF)
555Translocation t(3;3)(q21;q26) and thrombocytosis
Cancer Genetics and Cytogenetics, 1986, 22, 365
1.29Citations (PDF)
556Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphoma
OncoImmunology, 0, , e1321184
5.423Citations (PDF)